US20110274594A1 - Ab-remover, ab-removing apparatus, and ab removal method - Google Patents

Ab-remover, ab-removing apparatus, and ab removal method Download PDF

Info

Publication number
US20110274594A1
US20110274594A1 US13/166,431 US201113166431A US2011274594A1 US 20110274594 A1 US20110274594 A1 US 20110274594A1 US 201113166431 A US201113166431 A US 201113166431A US 2011274594 A1 US2011274594 A1 US 2011274594A1
Authority
US
United States
Prior art keywords
amyloid
protein
adsorption
carrier
sample name
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/166,431
Other languages
English (en)
Inventor
Nobuya Kitaguchi
Kazunori Kawaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujita Health University
Kaneka Corp
Original Assignee
Fujita Health University
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujita Health University, Kaneka Corp filed Critical Fujita Health University
Assigned to KANEKA CORPORATION, FUJITA HEALTH UNIVERSITY reassignment KANEKA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAWAGUCHI, KAZUNORI, KITAGUCHI, NOBUYA
Publication of US20110274594A1 publication Critical patent/US20110274594A1/en
Assigned to KANEKA CORPORATION reassignment KANEKA CORPORATION CHANGE OF ADDRESS Assignors: KANEKA CORPORATION
Priority to US14/060,074 priority Critical patent/US9061108B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3479—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by dialysing the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3204—Inorganic carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/07—Proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • the present invention relates to an A ⁇ remover for removing an amyloid ⁇ protein (A ⁇ ) from a body fluid.
  • the invention also relates to an A ⁇ removing apparatus and an A ⁇ removal system which use the A ⁇ remover.
  • Alzheimer's disease is cognitive disorder that denatures intracerebral nerve cells due to accumulating an amyloid ⁇ protein (hereinafter, abbreviated as “A ⁇ ”) in the brain.
  • a ⁇ amyloid ⁇ protein
  • the most prevailing is the “amyloid hypothesis” such that soluble A ⁇ strongly inhibits long-term enhancement of memory and A ⁇ that is coagulated and deposited forms fibrils to thus lead nerve cells to death.
  • Non-patent Document 1 Due to administration of an antibody against A ⁇ (anti-A ⁇ antibody) and administration of an A ⁇ vaccine, deletion of A ⁇ deposition in the brain as well as improvement in symptoms of cognitive disorder were reported, and possibility that Alzheimer's disease can be treated was shown (Non-patent Document 1).
  • administration of an A ⁇ vaccine caused death for side effects and a clinical trial was thus ceased (Non-patent Document 2); accordingly, the goal to establishing a therapeutic method for Alzheimer's disease is far.
  • development of an anti-A ⁇ antibody excellent in therapeutic effects has progressed by a number of research groups, but a therapy with an anti-A ⁇ antibody is expensive and takes over a long period of time, and thus, burden on a patient is severe.
  • an anti-A ⁇ antibody has a problem such that its effects are comparatively short, which thus requires repeated administrations.
  • Patent Documents 1 and 2 are shown as prior art documents.
  • Patent Document 1 Japanese Unexamined Patent Application Publication (JP-A) No. 2005-537254
  • Patent Document 2 JP-A No. 2008-50665
  • Non-patent Document 1 Bayer A et al., Neurology 2005; 64: 94-101.
  • Non-patent Document 2 Holmes C et al.: Lancet. 2008 Jul. 19; 372(9634): 216-23.
  • Non-patent Document 3 Lemere, C. A. et al.: Nuerobiol. Dis., 14: 10-18, 2003
  • Non-patent Document 4 Matsuoka Y, et al.: J. Neurosci., 23: 29-33, 2003
  • Non-patent Document 5 Bergamaschini, L. et al.: J. Neurosci., 24:4148-4186, 2004
  • Non-patent Document 6 Levites, Y. et al.: J. Neurosci., 26: 11923-11928, 2006
  • Non-patent Document 7 Kyoto Medical Journal, Vol. 53, No. 1, June, 2006, pp. 113 to 120
  • Non-patent Document 8 Isabel Rubio et al., Journal of Alzheimer's Disease 10 (2006) 439-443
  • Non-patent Document 9 CE Technical Series, Hemocatharsis Therapy, Takashi Akiba, Michio Mineshima, p. 228 (Nankodo Co., Ltd.)
  • a ⁇ adsorption abilities (removal abilities) of existing medical adsorbing materials were evaluated in comparison.
  • high A ⁇ adsorption abilities were shown in an adsorbent obtained by fixing a hexadecyl group (C 16 ) as a ligand to a carrier made of cellulose beads, an adsorbent obtained by covering a surface of a bead-like activated carbon with a hydrophilic polymer, and an adsorbent obtained by fixing tryptophan as a ligand to a carrier made of a polyvinyl alcohol gel.
  • a prompt effect is obtained.
  • a blood A ⁇ concentration can he decreased in a few hours. Decrease in an intracerebral A ⁇ concentration with the decrease in the blood A ⁇ concentration can be expected.
  • the method can be inexpensively carried out as compared to an immunotherapy, etc.
  • the present invention is mainly based on the above described findings and results.
  • the present invention is as follows:
  • FIG. 1 is a schematic view of an extracorporeal circulation system into which an A ⁇ removing apparatus is incorporated (one example).
  • the blood is continuously supplied to an A ⁇ removing apparatus (column filled with A ⁇ remover) with a pump to be treated.
  • a ⁇ in the blood is removed by the A ⁇ removing apparatus (1).
  • the system enables A ⁇ in the intracorporeal circulating blood to decrease (2) and promotes transfer of intracerebral A ⁇ into a blood vessel (3). As a result, improvement in cognitive disorder is attempted.
  • FIG. 2 is a graph showing an A ⁇ 1-40 adsorption ability of an existing medical adsorbing material.
  • the vertical axis shows an A ⁇ 1-40 adsorption ratio.
  • FIG. 3 is a graph showing an A ⁇ 1-42 adsorption ability of an existing medical adsorbing material.
  • the vertical axis shows an A ⁇ 1-42 adsorption ratio.
  • FIG. 4 is a graph showing time lapse change of an A ⁇ 1-40 adsorption ability of an existing medical adsorbing material.
  • the horizontal axis shows a time elapsed (hours), and the vertical axis shows an A ⁇ 1-40 residual ratio in a solution (100 ⁇ adsorption ratio (%)).
  • Adsorption abilities were compared using simulated plasma.
  • FIG. 5 is a graph showing time lapse change of an A ⁇ 1-42 adsorption ability of an existing medical adsorbing material.
  • the horizontal axis shows a time elapsed (hours), and the vertical axis shows an A ⁇ 1-42 residual ratio in a solution (100 ⁇ adsorption ratio (%)).
  • Adsorption abilities were compared using simulated plasma.
  • FIG. 6 is a graph showing time lapse change of an A ⁇ 1-40 adsorption ability of an existing medical adsorbing material.
  • the horizontal axis shows a time elapsed (hours), and the vertical axis shows an A ⁇ 1-40 residual ratio in a solution (100 ⁇ adsorption ratio (%)).
  • Adsorption abilities were compared using human fresh frozen plasma (FFP).
  • FIG. 7 is a graph showing time lapse change of an A ⁇ 1-42 adsorption ability of an existing medical adsorbing material.
  • the horizontal axis shows a time elapsed (hours), and the vertical axis shows an A ⁇ 1-42 residual ratio in a solution (100 ⁇ adsorption ratio (%)).
  • Adsorption abilities were compared using human fresh frozen plasma (FFP).
  • FIG. 8 is a graph showing an A ⁇ 1-40 adsorption ability of an existing medical adsorbing material (in the case where simulated plasma was continuously treated).
  • the horizontal axis shows a time elapsed (minutes), and the vertical axis shows an A ⁇ 1-40 concentration at a column outlet (ng/ml).
  • Lx Lixelle
  • Hm Hemosorba
  • Im Immusorba.
  • FIG. 9 is a graph showing an A ⁇ 1-42 adsorption ability of an existing medical adsorbing material (in the case where simulated plasma was continuously treated).
  • the horizontal axis shows a time elapsed (minutes), and the vertical axis shows an A ⁇ 1-42 concentration at a column outlet (ng/ml).
  • Lx Lixelle.
  • FIG. 10 is a graph showing an A ⁇ 1-42 adsorption ability of an existing medical adsorbing material (in the case where simulated plasma was continuously treated).
  • the horizontal axis shows a time elapsed (minutes), and the vertical axis shows an A ⁇ 1-42 concentration at a column outlet (ng/ml).
  • Hm Hemosorba.
  • FIG. 11 is a graph showing an A ⁇ 1-40 adsorption ability of a silica carrier having a linear alkyl chain on the surface.
  • the horizontal axis shows a time elapsed (hours), and the vertical axis shows an A ⁇ 1-40 residual ratio in a solution (100 ⁇ adsorption ratio (%)).
  • the relationship between the length of the linear alk y l chain and the adsorption ability was examined in comparison using simulated plasma. Carbon contents of respective samples are C0: 0%, C2: 5.5%, C8: 12%, and C18: 19%.
  • FIG. 12 is a graph showing an A ⁇ 1-40 adsorption ability of a cellulose carrier.
  • the horizontal axis shows a time elapsed (hours), and the vertical axis shows an A ⁇ 1-40 residual ratio in a solution (100 ⁇ adsorption ratio (%)).
  • FIG. 13 shows an overview of a blood purification experiment.
  • a column filled with Lx (Lixelle) and a dialysis apparatus were serially connected and the blood was circulated.
  • a dialysis apparatus was solely used (comparative example).
  • FIG. 14 shows results of the blood purification experiment. An A ⁇ 1-40 concentration at each point in the case where a column filled with Lx (Lixelle) and a dialysis apparatus were used in combination is shown.
  • FIG. 15 shows results of the blood purification experiment. A removal ratio of A ⁇ 1-40 is shown. The upper shows an A ⁇ 1-40 removal ratio in the case where a column filled with Lx (Lixelle) and a dialysis apparatus were used in combination, and the lower shows an A ⁇ 1-40 removal ratio in the case where a dialysis apparatus was solely used.
  • FIG. 16 shows results of the blood purification experiment (comparative example). An A ⁇ 1-40 concentration at each point in the case where a dialysis apparatus was solely used is shown.
  • FIG. 17 shows results of the blood purification experiment (Example 12). Concentrations and removal ratios of A ⁇ 1-40 and A ⁇ 1-42 at each point in the case where a column tilled with the sample name Lx and a dialysis apparatus were used in combination are shown.
  • FIG. 18 is graphs showing a removal ratio of A ⁇ 1-40 (left) or A ⁇ 1-42 (right).
  • Cellulose beads having a linear alkyl chain (C0, C2, C4, C8, C16 or C22) on the surface were used as A ⁇ adsorbents.
  • the horizontal axis shows a time elapsed (hours).
  • FIG. 19 is graphs showing a removal ratio of A ⁇ 1-40 (left) or A ⁇ 1-42 (right).
  • Silica beads having a linear alkyl chain (C0, C2, C8 or C18) on the surface were used as A ⁇ adsorbents.
  • the horizontal axis shows a time elapsed (hours).
  • FIG. 20 shows a relationship between the removal ratio of A ⁇ 1-40 (left) or A ⁇ 1-42 (right) and the length of alkyl chain for both cellulose and silica carriers.
  • the first aspect of the present invention relates to an amyloid ⁇ protein (A ⁇ ) remover.
  • a ⁇ is constituted with 40 to 43 amino acids and is produced from a precursor (APP: amyloid ⁇ protein precursor) by functions of ⁇ and ⁇ secretases.
  • Main molecular species are A ⁇ 1-40 and A ⁇ 1-42. Strong neurotoxicity is recognized in the latter.
  • the “A ⁇ remover” of the present invention is excellent in adsorption property to A ⁇ and can remove A ⁇ from a solution containing A ⁇ .
  • Materials of a carrier constituting the A ⁇ remover of the present invention are cellulose, silica, polyvinyl alcohol or activated carbon.
  • no alkyl chain exists on the surface of the carrier.
  • an alkyl chain having 1 to 22 carbon atoms is present on the surface of the carrier.
  • Lixelle of a cellulose carrier and Hemosorba of an activated carbon carrier showed excellent A ⁇ adsorption abilities.
  • a material of a carrier is preferably cellulose or activated carbon.
  • the surfaces thereof are preferably covered with a hydrophilic polymer.
  • a hydrophilic polymer are not particularly limited.
  • a polymer of methacrylic acid 2-hydroxyethyl ester, polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), or the like can be adopted as a hydrophilic polymer.
  • a material of a carrier is silica and no alkyl chain exists on the surface of the carrier.
  • a material of a carrier is silica and an alkyl chain having 2 to 18 carbon atoms is bound to the surface of the carrier via a silanol group. It is preferable that the number of carbon atoms in an alkyl group is less, and the number is preferably 1 to 5, and more preferably 1 to 2.
  • a material of a carrier is cellulose and an alkyl chain having 2 to 22 carbon atoms is bound to the surface of the carrier.
  • the number of carbon atoms in an alkyl chain is preferably 16 to 22.
  • a ⁇ removal from actual patient's blood it is preferred to select an A ⁇ remover also in consideration of evaluations of blood compatibility such as low antithrombogenicity and low complement activation.
  • a commercially available medical adsorbing material can be used as a carrier constituting, the A ⁇ remover of the present invention.
  • a preferable medical adsorbing material include Lixelle (trade name: KANEKA CORPORATION), Immusorba (trade name: Asahi Kasei Kuraray Medical Co., Ltd.), and Hemosorba (trade name: Asahi Kasei Kuraray Medical Co., Ltd.).
  • Lixelle has a structure in which a hexadecyl group is bound to the surface of cellulose beads as a ligand.
  • Immusorba is a material having a polyvinyl alcohol gel as a carrier and tryprophane (Immusorba TR) or phenylalanine (Immusorba PH) as a ligand.
  • Hemosorba is a carrier made of petroleum pitch-based bead-like activated carbon, and the surface thereof is covered with a polymer of methacrylic acid 2-hydroxyethyl ester.
  • a shape of the A ⁇ adsorbing material of the present invention is not particularly limited.
  • the shape include granule, gel, porous body, and hollow fiber, which are fixation materials to a surface.
  • An average particle size in the case of a granular shape is, for example. 1 ⁇ m to 5 mm, preferably 30 ⁇ m to 3 mm, and more preferably 50 ⁇ m to 800 ⁇ m.
  • the A ⁇ adsorbing material of the present invention is utilized for removing A ⁇ in a body fluid. That is, use of the A ⁇ adsorbing material of the present invention is removal of A ⁇ in a body fluid.
  • “removal” means removing at least a part of A ⁇ that is present in a body fluid, and includes both partial removal and complete removal.
  • an A ⁇ remover is contained in a container provided with an inlet and an outlet to form an A ⁇ removing apparatus, and a body fluid is passed through the A ⁇ removing apparatus.
  • the container is typically in a column shape, and is not limited thereto. According to a column filled with an A ⁇ remover, a system excellent in operation ability can be constructed.
  • the shape of the column is desirably in a shape such that the blood flows uniformly and with less pressure resistance.
  • An elongated shape is preferable in order to increase an A ⁇ removal ratio between the inlet and the outlet of the column, and on the other hand, a thick and short shape is preferable in order to decrease pressure resistance: therefore, a suitable shape may be selected depending on a size (particulate diameter) of an A ⁇ remover.
  • an A ⁇ removal system extractcorporeal circulation system
  • the pump is for supplying a body fluid to the A ⁇ removing apparatus continuously, and the structure thereof, etc are not particularly limited as long as the function is provided.
  • a pump for a blood purification apparatus a pump for a dialysis treatment, a perista pump (roller pump), and the like can be used.
  • Two or more A ⁇ removing apparatuses are prepared and these may be serially connected.
  • two or more A ⁇ removing apparatuses filled with different A ⁇ removers had better be used in combination.
  • a system capable of efficiently removing both A ⁇ 1-40 and A ⁇ 1-42 can be constructed.
  • a liquid treated by the A ⁇ removal system of the present invention is a body fluid.
  • blood e.g., peripheral blood
  • cerebrospinal fluid, and the like are treated.
  • a body fluid after separating specific components in advance e.g., plasma and serum
  • plasma and serum can be provided in the treatment.
  • a dialysis apparatus dialyzer
  • a dialysis apparatus that is an A ⁇ removal means based on an action mechanism different from the A ⁇ removing apparatus of the present invention is incorporated to intend improvement in an A ⁇ removal ratio.
  • use of a dialysis apparatus in combination enables increase of an A ⁇ removal ratio (see examples described later).
  • a dialysis apparatus may be a hollow fiber type dialysis apparatus or a multilayer type (kiil type) dialysis apparatus.
  • a material of a dialysis membrane constituting the dialysis apparatus is not particularly limited. As showing a part of examples, polyethylene resin, polystyrene resin, polysulfone resin, polyether sulfone resin, polymethyl methacrylate resin, cellulose acetate resin, and acrylonitrile-sodium methallyl sulfonate copolymer are included. Additionally, a dialysis apparatus utilizing a dialysis membrane with a large hole, which is called a high performance membrane, can also be used.
  • a dialysis apparatus can be connected to an A ⁇ removing apparatus serially or parallelly, and in the case of serial connection, a body fluid treated by the dialysis apparatus is sequentially treated by the A ⁇ removing apparatus, or a body fluid treated by the A ⁇ removing apparatus is sequentially treated by the dialysis apparatus.
  • Use of two or more dialysis apparatuses is also possible. In this case, for example, dialysis apparatuses can be respectively arranged in front and back of an A ⁇ removing apparatus.
  • an A ⁇ removal means using a substance having a specific binding property to A ⁇ may be used in combination.
  • Typical examples of the “substance having a specific binding property to A ⁇ ” herein include anti-A ⁇ antibodies (may be antibody fragments of Fab, Fab′, F(ab′) 2 , scFv, dsFv antibodies), Gelsolin, and GM1 Ganglioside, and the substance is not limited thereto as long as it has a specific binding property to A ⁇ .
  • a pressure meter As other factors that can be included in the A ⁇ removal system of the present invention, a pressure meter, a flow rate detector, an abnormal action detector, in the case of a granular A ⁇ remover, a particulate removing filter, an air chamber and a hemolytic sensor can be exemplified.
  • acetic acid cellulose beads (the sample name is referred to as “Ad”, manufactured by JIMRO Co., Ltd., product name: Adacolumn (trade name)), and one sixth (64 degrees out of 360 degrees) of 1 cm-width cross-sectional polyester nonwoven fabric (the sample name is referred to as “CS”, manufactured by Asahi Kasei Kuraray Medical Co., Ltd., product name: Cellsorba (trade name)) were respectively taken out from a sterilized container, charged in a 15 ml-centrifuging tube made of polypropylene (hereinafter referred to as “PP”), and washed with 10 ml of a phosphate sodium chloride buffer (hereinafter referred to as PBS( ⁇ )) three times, thereafter adding 10 ml of a PBS( ⁇ ) solution with 12 ng/ml of A ⁇ 1-40 (manufactured by Wako Pure Chemical Industries, Ltd.).
  • PP polypropylene
  • One eightieth of an amount used in a column in clinical use for an adult was used as a target for an amount of each sample.
  • 10 ml of the A ⁇ solution corresponds to about 1/400 of a blood amount that is clinically treated, and the A ⁇ concentration is set in reference to a blood A ⁇ concentration that increases in anti-A ⁇ antibody administration, which is approximately 100 times of a general blood A ⁇ concentration.
  • an experiment was designed so as to increase load to each sample.
  • 10 mg/ml of bovine serum albumin (Wako Pure Chemical Industries, Ltd., fatty acid/globulin free, hereinafter referred to as “BSA”) was added to form simulated plasma.
  • BSA bovine serum albumin
  • a ⁇ 1-40 adsorption abilities were measured on 3 materials of Hm, Im and Lx under room temperature at each point of shaking times of 1 hour, 4 hours, and 16 hours.
  • the experimental conditions were in accordance with Example 1.
  • a ⁇ 1-40 decrease ratios (adsorption ratios) when that of the control at each time was assumed to be 100% were sample name Hm: 92.8%, sample name Im: 63.4%, and sample name Lx: 93.0% at the time point of 1 hour; sample name Hm: 93.5%, sample name Im: 58.6%, and sample name Lx: 93.9% at the time point of 4 hours; and sample name Hm: 93.0%, sample name Im: 66.8%, and sample name Lx: 90.2% at the time point of 16 hours ( FIG. 4 ). It was found that Hm and Lx adsorb A ⁇ 1-40 rapidly and efficiently. In addition. desorption of A ⁇ 1-40 after adsorption was not observed.
  • a ⁇ 1-42 adsorption abilities were measured on 3 materials of Hm, Im and Lx under room temperature at each point of shaking times of 1 hour, 4 hours, and 16 hours.
  • the experimental conditions were in accordance with Example 2.
  • a ⁇ 1-42 decrease ratios (adsorption ratios) when that of the control at each time was assumed to be 100% were sample name Hm: 91.6%.
  • FFP human fresh frozen plasma
  • a ⁇ 1-40 adsorption abilities were measured on 3 materials of Hm, Im and Lx under room temperature at each point of shaking times of 4 hours and 16 hours, using the FFP thus collected in place of a 10 mg/ml BSA/PBS( ⁇ ) solution.
  • a ⁇ 1-40 peptide was added to this FFP to adjust a final concentration at 22.0 ng/ml that was approximately 100 times.
  • the experimental conditions were in accordance with Example 1.
  • a ⁇ 1-42 adsorption abilities were measured on 3 materials of Hm, Im and Lx under room temperature at each point of shaking times of 0.5 hour, 1 hour and 16 hours, using FFP collected in the same manner as in Example 5 in place of a 10 mg/ml BSA/PBS( ⁇ ) solution.
  • the concentration of A ⁇ 1-42/FFP brought into contact with an adsorbing material was 23.8 ng/ml, which was approximately 1000 times as high as the A ⁇ 1-42 concentration of FFP itself of 23.4 pg/ml.
  • the experimental conditions were in accordance with Example 2.
  • a material to be evaluated was filled in a 2.5 mL-cylindrical miniature column (a column size for an adsorbing material portion in the case of the sample name Lx is 9 mm in diameter and 30 mm in length), and a 10 mg/mL BSA/PBS( ⁇ ) solution was primed with a perista pump at a flow rate of 10 ml/hr for 90 minutes. Then, a liquid flown to the material was converted to a 10 mg/ml BSA/PBS( ⁇ ) solution containing A ⁇ 1-40 at about 30 ng/ml being the same as Example 1, and the solution was passed through the material at the same flow rate for 120 minutes (sample name Hm and sample name Im) or 300 minutes (sample name Lx).
  • An A ⁇ 1-40 concentration in the liquid after passing through the material was measured in the same manner as in Example 1. This system assumes 1/200 of a human clinical application and simulates treating 4 L of plasma in 2 hours. Measurement results are shown in FIG. 8 .
  • the adsorption ability to A ⁇ 1-40 was Im ⁇ Hm ⁇ Lx. Lx and Hm showed sufficient adsorption abilities event to A ⁇ at an about 100 times higher concentration than an actual blood A ⁇ concentration.
  • a material to be evaluated was filled in a 2.5 mL-cylindrical miniature column (a column size for an adsorbing material portion in the case of the sample name Lx is 9 mm in diameter and 30 mm in length), and a 10 mg/mL BSA/PBS( ⁇ ) solution was primed with a perista pump at a flow rate of 10 ml/hr for 90 minutes.
  • a liquid flown to the material was then converted to a 10 mg/ml BSA/PBS( ⁇ ) solution containing A ⁇ 1-42 at about 30 ng/ml being the same as Example 2, and the solution was passed through the material at the same flow rate for 120 minutes (sample name Hm) or 300 minutes (sample name Lx).
  • Example 2 An A ⁇ 1-42 concentration in the liquid after passing through the material was measured in the same manner as in Example 2. This system assumes 1/200 of a human clinical application and simulates treating 4 L of plasma in 2 hours.
  • the measurement results of two experiments on the sample name Lx (Lx-G, Lx-H) are shown in FIG. 9
  • the measurement results of two experiments on the sample name Hm are shown in FIG. 10 .
  • Lx and Hm showed sufficient adsorption abilities event to A ⁇ at an about 100 times higher concentration than an actual blood A ⁇ concentration.
  • Example name C0 (bead diameter 120 ⁇ m, pore diameter 6 nm, specific surface area 450 m 2 /g, pore volume 0.7 ml/g)
  • a carrier having an ethyl group (sample name C2)
  • a carrier having an octyl group (sample name C8)
  • a carrier having an octadecyl group (sample name C18) were used.
  • respective carbon contents were C0: carbon content 0%.
  • C2 carbon content 5.5%.
  • C8 carbon content 12%
  • C18 carbon content 19%.
  • a ⁇ 1-40 adsorption ability of a cellulose carrier without having a linear alkyl chain on the surface was measured according to Example 1 and Example 3.
  • Viscopearl-mini PD4002 manufactured by Rengo Co., Ltd. (bead diameter 400 ⁇ m, specific surface area 1 to 10 m 2 /g) was used.
  • a ⁇ 1-40 decrease ratios (adsorption ratios) measured under room temperature ‘at each point of shaking times of 0.5 hour, 1 hour, 4 hours and 16 hours when that of the control at each time was assumed to be 100% were 93.7%, 95.3%, 100.0%, and 101.1%, respectively ( FIG. 12 ).
  • a cellulose bead that is a hydrophilic carrier also showed a significantly excellent A ⁇ adsorption ability.
  • a blood purification column of Lx (Lixelle S-15, KANEKA CORPORATION) and a dialyzer (made of PMMA, TORAY MEDICAL Co., Ltd.) were serially connected in this order from the blood removal side ( FIG. 13( a )), to carry out blood purification by extracorporeal circulation of a renal failure patient (purification with sample name Lx and dialysis treatment) for 4 hours.
  • a ⁇ 1-40 in the patient's blood before initiation of the dialysis was about 596 pg/ml
  • a ⁇ 1-40 in the inlet of the column for the sample name Lx at 1 hour alter initiation of the dialysis was about 334 pg/ml
  • a ⁇ 1-40 in the outlet of the column for the sample name Lx was about 170 pg/ml
  • a ⁇ 1-40 in the dialyzer outlet was about 90 pg/ml
  • a ⁇ 1-40 in the patient's blood at completion of the dialysis was about 350 pg/ml ( FIG. 14) .
  • An A ⁇ concentration decrease ratio of the patient's circulating blood before and after the dialysis was 41.3%
  • an A ⁇ removal ratio before and after the column for the sample name Lx was 49.0%
  • an A ⁇ concentration decrease ratio of the patient's circulating blood at 1 hour after initiation of the dialysis was 44% (upper column in FIG. 15 ).
  • Lx was able to efficiently remove A ⁇ .
  • combination use of a dialysis apparatus made it possible to improve an A ⁇ removal ratio.
  • a dialysis treatment was carried out with a dialyzer (made of PMMA, TORAY MEDICAL Co., Ltd.) in the same manner as in Example 10 (different patient from the patient in Example 10) except for not using a blood purification column of Lx (Lixelle S-15, KANEKA CORPORATION).
  • the patient's blood was collected before initiation of the dialysis, at 1 hour after initiation of the dialysis, and at completion of the dialysis to measure blood A ⁇ 1-40 concentrations in the same manner as in Example 1.
  • the A ⁇ concentration decrease ratio of the patient's circulating blood before and after the dialysis was 25.0%
  • the A ⁇ concentration decrease ratio of the patient's circulating blood at 1 hour after initiation of the dialysis was 17.5% (lower column in FIG. 15 ).
  • the A ⁇ decrease ratios were significantly lowered as compared to the case where an Lx column and a dialysis apparatus were used in combination (Example 11).
  • the blood purification of 4 hours was carried out on two renal failure patients (referred to as patient A and patient B) in the same method as in Example 11 (provided that a dialysis apparatus made of PS (Asahi Kasei Kuraray Medical Co., Ltd.) was used).
  • patient A and patient B The blood purification of 4 hours was carried out on two renal failure patients (referred to as patient A and patient B) in the same method as in Example 11 (provided that a dialysis apparatus made of PS (Asahi Kasei Kuraray Medical Co., Ltd.) was used).
  • the patient's blood before initiation of the dialysis, and the patient's blood in the inlet and the outlet of the column for the sample name Lx at 1 hour and 4 hours after initiation of the dialysis were collected, to measure blood A ⁇ 1-40 concentrations and blood A ⁇ 1-42 concentrations in the same manner as in Example 1 and Example 2.
  • the results were shown in FIG. 17 .
  • a ⁇ 1-40 concentration decrease ratios of the patient's circulating blood before and after the dialysis were patient A; 51.8%, patient B; 43.9%, and A ⁇ 1-42 concentration decrease ratios were patient A; 43.3% and patient B; 34.4%. Namely. similarly to Example 11. A ⁇ 1-40 and A ⁇ 1-42 were able to be efficiently removed by Lx also in other two patients.
  • the A ⁇ removal ratios of cellulose beads after 4 hours of shaking are: 9.9% (A ⁇ 1-40) and 17.0% (A ⁇ 1-42) for C0: 99.6% (A ⁇ 1-40) and 99.4% (A ⁇ 1-42) for C22.
  • the A ⁇ removal ratios of silica beads after 4 hours of shaking are: 98.6% (A ⁇ 1-40) and 97.5% (A ⁇ 1-42) for C0; 40.0% (A ⁇ 1-40) and 19.6% (A ⁇ 1-42) for C18.
  • interesting relationships are observed between the removal ratio of A ⁇ and the length of alkyl chain ( FIG. 20 ) for both cellulose and silica carriers.
  • the A ⁇ remover of the present invention is excellent in A ⁇ removal ability. According to an extracorporeal circulation system into which the A ⁇ remover of the invention is incorporated, a therapeutic or preventive method for Alzheimer's disease, which has less side effects, attains prompt effects, and is also inexpensively practicable, can be achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • External Artificial Organs (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US13/166,431 2008-12-22 2011-06-22 Ab-remover, ab-removing apparatus, and ab removal method Abandoned US20110274594A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/060,074 US9061108B2 (en) 2008-12-22 2013-10-22 Aβ-remover, Aβ-removing apparatus, and Aβ removal method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-326174 2008-12-22
JP2008326174 2008-12-22
PCT/JP2009/007051 WO2010073580A1 (ja) 2008-12-22 2009-12-21 Aβ除去材、Aβ除去器及びAβ除去システム

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/007051 Continuation-In-Part WO2010073580A1 (ja) 2008-12-22 2009-12-21 Aβ除去材、Aβ除去器及びAβ除去システム

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/060,074 Continuation US9061108B2 (en) 2008-12-22 2013-10-22 Aβ-remover, Aβ-removing apparatus, and Aβ removal method

Publications (1)

Publication Number Publication Date
US20110274594A1 true US20110274594A1 (en) 2011-11-10

Family

ID=42287230

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/166,431 Abandoned US20110274594A1 (en) 2008-12-22 2011-06-22 Ab-remover, ab-removing apparatus, and ab removal method
US14/060,074 Active US9061108B2 (en) 2008-12-22 2013-10-22 Aβ-remover, Aβ-removing apparatus, and Aβ removal method

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/060,074 Active US9061108B2 (en) 2008-12-22 2013-10-22 Aβ-remover, Aβ-removing apparatus, and Aβ removal method

Country Status (7)

Country Link
US (2) US20110274594A1 (zh)
EP (1) EP2361645B1 (zh)
JP (1) JP5432923B2 (zh)
KR (1) KR101538361B1 (zh)
CN (2) CN102264411B (zh)
CA (1) CA2748561C (zh)
WO (1) WO2010073580A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
CN112351802A (zh) * 2018-07-02 2021-02-09 旭化成医疗株式会社 血液处理用珠

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921216A1 (en) * 2014-03-17 2015-09-23 ETH Zurich Heavy metal recycling process and material usefull in such process
JP6501425B2 (ja) * 2017-05-31 2019-04-17 学校法人藤田学園 Ａβ除去システム
JP7125892B2 (ja) * 2018-11-20 2022-08-25 株式会社クレハ アミロイドβ除去器具、生体由来液浄化システム、アミロイドβ除去方法およびアミロイドβ除去用吸着材
CN111569842A (zh) * 2020-06-02 2020-08-25 威海威高生命科技有限公司 一种复合型吸附剂及其制备方法
CN113057963B (zh) * 2021-03-31 2022-05-20 华中科技大学 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020034723A1 (en) * 2000-03-09 2002-03-21 Hans-Peter Leinenbach Adsorbent for reducing the concentration of fibrinogen and/or fibrin, method of producing an adsorber from the adsorbent, and an adsorber with the adsorbent
US20020192632A1 (en) * 1995-06-07 2002-12-19 Hei Derek J. Method and devices for the removal of psoralens from blood products
US20030150813A1 (en) * 2001-04-12 2003-08-14 Nobuyuki Hayashi Adsorbent device for body fluid treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
JPH0620549B2 (ja) * 1987-11-20 1994-03-23 鐘淵化学工業株式会社 血清アミロイドａ蛋白吸着体
US6551266B1 (en) * 1998-12-29 2003-04-22 Occulogix Corporation Rheological treatment methods and related apheresis systems
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
KR101139103B1 (ko) * 2003-09-12 2012-07-05 아피리스 아게 아페레시스 장치
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
ES2379987T3 (es) * 2005-10-11 2012-05-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compuestos de benzofurano marcados isotópicamente como radiotrazadores para proteínas amiloidógenas
JP5027591B2 (ja) * 2006-08-18 2012-09-19 株式会社カネカ 架橋ポリマー粒子およびその製法
JP2008050665A (ja) 2006-08-25 2008-03-06 Hitachi Metals Ltd マルテンサイト系ステンレス鋳鋼部品の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192632A1 (en) * 1995-06-07 2002-12-19 Hei Derek J. Method and devices for the removal of psoralens from blood products
US20020034723A1 (en) * 2000-03-09 2002-03-21 Hans-Peter Leinenbach Adsorbent for reducing the concentration of fibrinogen and/or fibrin, method of producing an adsorber from the adsorbent, and an adsorber with the adsorbent
US20030150813A1 (en) * 2001-04-12 2003-08-14 Nobuyuki Hayashi Adsorbent device for body fluid treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sulowicz et al., "Application of LDL-apheresis and immunoadsorption in kidney diseases", Roczniki Akademii Medycznej w Bialymstoku, Vol. 49, 2004, pages 127-134. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
CN112351802A (zh) * 2018-07-02 2021-02-09 旭化成医疗株式会社 血液处理用珠
US11850345B2 (en) 2018-07-02 2023-12-26 Asahi Kasei Medical Co., Ltd. Beads for blood processing
US11850346B2 (en) 2018-07-02 2023-12-26 Asahi Kasei Medical Co., Ltd. Beads for blood processing

Also Published As

Publication number Publication date
EP2361645A1 (en) 2011-08-31
JP5432923B2 (ja) 2014-03-05
CN104274875A (zh) 2015-01-14
EP2361645B1 (en) 2014-10-29
CA2748561C (en) 2016-11-01
CA2748561A1 (en) 2010-07-01
US9061108B2 (en) 2015-06-23
JPWO2010073580A1 (ja) 2012-06-07
KR101538361B1 (ko) 2015-07-22
WO2010073580A1 (ja) 2010-07-01
KR20110122097A (ko) 2011-11-09
CN102264411A (zh) 2011-11-30
CN102264411B (zh) 2014-10-22
EP2361645A4 (en) 2012-07-04
US20140042098A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US9061108B2 (en) Aβ-remover, Aβ-removing apparatus, and Aβ removal method
US11844895B2 (en) Method for removing bacteria from blood using high flow rate
JP6072189B2 (ja) 表面固定した多糖類を用いた、血液からのサイトカイン除去法
TW389705B (en) Affinity membrane system and method of using same
US8771513B2 (en) Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof
JP5843345B2 (ja) β−アミロイド除去システム
WO2013062479A1 (en) A method for extracorporeal elimination of one or more components from blood
AU2020274735A1 (en) Method for modulating endothelial glycocalyx structure
US9265875B2 (en) Methods for treating blood composition and function disorders wherein a patient's blood plasma is extracorporeally contacted with donor blood or modified donor blood
US20050009001A1 (en) Device for removing bacterial lipopolysaccharides and/or lipoteichoic acids from protein-containing fluids and its use for the treatment of sepsis
JP3748927B2 (ja) 糖脂質抗体吸着材
CN106267407A (zh) 母胎Rh血型不合血液净化治疗仪
JP2019193709A (ja) アミロイド−β除去システム
JPH10328565A (ja) 免疫複合体の除去装置
DD265470A1 (de) Spezifisches adsorbens zur bindung von anti-dna-autoantikoerpern

Legal Events

Date Code Title Description
AS Assignment

Owner name: FUJITA HEALTH UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KITAGUCHI, NOBUYA;KAWAGUCHI, KAZUNORI;REEL/FRAME:026577/0068

Effective date: 20110602

Owner name: KANEKA CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KITAGUCHI, NOBUYA;KAWAGUCHI, KAZUNORI;REEL/FRAME:026577/0068

Effective date: 20110602

AS Assignment

Owner name: KANEKA CORPORATION, JAPAN

Free format text: CHANGE OF ADDRESS;ASSIGNOR:KANEKA CORPORATION;REEL/FRAME:031207/0283

Effective date: 20130107

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION